TherapeuticsMD, Inc. reported a net loss of $569,000 for the fiscal year ending December 31, 2025, a significant improvement compared to a net loss of $2.2 million in 2024. The company's revenue for 2025 was $3.0 million, primarily derived from royalties under the Mayne License Agreement, reflecting a 71.6% increase from $1.8 million in the previous year. This growth in revenue is attributed to the performance of licensed products, including IMVEXXY and BIJUVA, which are now commercialized by Mayne Pharma following a strategic shift in the company's business model to a pharmaceutical royalty company in December 2022.
Operating expenses for the year totaled $7.4 million, a decrease of 5.9% from $7.9 million in 2024. The reduction in expenses was mainly due to lower impairment charges, although general and administrative costs rose by 12.4% to $6.9 million, driven by increased bonuses and investor relations expenses. The company also recognized a write-off of $176,000 for abandoned patents, a decrease from $1.3 million in 2024. The loss from operations decreased by 28.2% to $4.4 million, reflecting improved operational efficiencies as a royalty-based business.
In terms of strategic developments, TherapeuticsMD completed the Mayne Transaction on December 30, 2022, which involved granting Mayne Pharma exclusive rights to commercialize several products and resulted in a total cash consideration of $140 million. The agreement includes milestone payments based on sales performance, with potential additional payments of up to $30 million. The company has also entered into licensing agreements with Knight Therapeutics and Theramex for the commercialization of its products outside the U.S., further expanding its market reach.
As of December 31, 2025, TherapeuticsMD employed one full-time employee and relied on external consultants for operational support. The company has faced challenges related to its ongoing disputes with Mayne Pharma, including a lawsuit filed in April 2025 concerning breach of contract and other claims. The outcome of these legal matters remains uncertain and could impact the company's financial position. Additionally, there is substantial doubt about the company's ability to continue as a going concern, as it may need to raise capital to fund operations in the future.
Looking ahead, TherapeuticsMD's future revenue will depend heavily on the sales performance of its licensed products and the resolution of its legal disputes. The company is exploring various strategic alternatives to enhance its financial position, but the success of these efforts is contingent on market conditions and the performance of its licensees. The management remains focused on minimizing operating expenses and maximizing royalty income to ensure the sustainability of its operations.
About TherapeuticsMD, Inc.
TherapeuticsMD is a pharmaceutical royalty company specializing in women’s health products. It owns or licenses rights to products like IMVEXXY, BIJUVA, and ANNOVERA, generating revenue through royalties from licensed pharmaceutical products sold worldwide. The company focuses on licensing, patent protection, and strategic partnerships, relying on third-party manufacturers and licensees to commercialize its portfolio in various global markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.